Search - tctmd.com

Displaying 381 - 400 of 1216

Sort: Relevancy | Date

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

News Daily News

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

July 09, 2021

CTO PCI Ups Survival Amid High Ischemia Burden in Single-Center Registry

News Daily News

CTO PCI Ups Survival Amid High Levels of Ischemia in Single-Center Series

Yael L. Maxwell

July 05, 2021

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

News Daily News

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

Yael L. Maxwell

July 01, 2021

Complete Revascularization Best for Most ACS Patients With MVD

News Daily News

Complete Revascularization Best for Most ACS Patients With MVD

Michael O'Riordan

June 25, 2021

Statins Not Linked to Dementia or Memory Changes: ASPREE

News Daily News

Statins Not Linked to Dementia or Memory Changes: ASPREE

Michael O'Riordan

June 21, 2021

Closing the Gender Gap in Cardiology Clinical Trial Leadership: A Road Map

News Daily News

Closing the Gender Gap in Cardiology Clinical Trial Leadership: A Road Map

June 11, 2021

Comparable 10-Year Mortality in Elderly Patients After PCI or CABG: SYNTAXES

News Daily News

Comparable 10-Year Mortality in Elderly Patients After PCI or CABG: SYNTAXES

Michael O'Riordan

May 31, 2021

COLCORONA: Mixed Results for Colchicine in Nonhospitalized COVID-19

News Daily News

COLCORONA: Mixed Results for Colchicine in Nonhospitalized COVID-19

May 28, 2021

Cooling OHCA Patients to 31°C Not Superior to 34°C: CAPITAL-CHILL

News Conference News ACC 2021

Cooling OHCA Patients to 31°C Not Superior to 34°C: CAPITAL-CHILL

May 26, 2021

FFR Doesn’t Beat Angio for Complete Revasc in STEMI: FLOWER-MI

News Conference News ACC 2021

FFR Doesn’t Beat Angio for Complete Revasc in STEMI: FLOWER-MI

May 25, 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

May 24, 2021

Transradial PCI Bests Femoral Access in Complex Cases: COLOR

News Conference News EuroPCR 2021

Transradial PCI Bests Femoral Access in Complex Cases: COLOR

Michael O'Riordan

May 21, 2021

COOL-AMI Fails to Show Benefit of Rapid Cooling in STEMI

News Conference News EuroPCR 2021

COOL-AMI Fails to Show Benefit of Rapid Cooling in STEMI

Yael L. Maxwell

May 20, 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

May 19, 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

News Conference News ACC 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Yael L. Maxwell

May 17, 2021

Use of a Rapid, High-Sensitivity Troponin Protocol Doesn’t Boost 1-Year Outcomes

News Conference News ACC 2021

Use of a Rapid, High-Sensitivity Troponin Protocol Doesn’t Boost 1-Year Outcomes

May 16, 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

News Conference News ACC 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

Michael O'Riordan

May 15, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.